Inflammatory bowel diseases ( IBD) are complex and multifactorial diseases that require a differentiated and evolving treatment approach. When monotherapies reach their limits, the need for combination strategies grows. The focus is on both conventional combination regimens and innovative applications of dual biological (targeted) therapies.
Partner
Autoren
- PD Dr. med. Pascal Juillerat
- Prof. Dr. med. Stephan Brand
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Proteins in wound healing
Do special amino acids lead to success?
- Psychedelic-assisted therapy
Current status of PAT
- Hepatitis B prophylaxis
Vaccination protection for healthcare staff with patient contact – an update
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Adrenogenital syndrome
Clinical care from birth to adulthood
- New approvals, current study data and ADC development
Antibody-drug conjugates in gynecologic oncology
- Type 2 diabetes: cardiovascular risk reduction is realistic
Modern active ingredients and lifestyle – every step counts
- From symptom to diagnosis